OK11 Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$4.35 |
| 52 Week Low | US$0.032 |
| Beta | -2.91 |
| 11 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | -60.00% |
| 33 Year Change | -94.63% |
| 5 Year Change | n/a |
| Change since IPO | -98.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| OK11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.1% |
| 1Y | -60.0% | -18.8% | 7.2% |
Return vs Industry: OK11 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: OK11 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| OK11 volatility | |
|---|---|
| OK11 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OK11's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OK11's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
OKYO Pharma Limited Fundamentals Summary
| OK11 fundamental statistics | |
|---|---|
| Market cap | €32.76m |
| Earnings (TTM) | -€7.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs OK11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OK11 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£4.39m |
| Gross Profit | -UK£4.39m |
| Other Expenses | UK£2.31m |
| Earnings | -UK£6.70m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OK11 perform over the long term?
See historical performance and comparison